Conduit Pharmaceuticals (FRA:ZK7) Land And Improvements : €0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Conduit Pharmaceuticals Land And Improvements?

Conduit Pharmaceuticals's land and improvements for the quarter that ended in Mar. 2025 was €0.00 Mil.

Conduit Pharmaceuticals Land And Improvements Historical Data

The historical data trend for Conduit Pharmaceuticals's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Land And Improvements Chart

Conduit Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Land And Improvements

Conduit Pharmaceuticals Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Land And Improvements	Get a 7-Day Free Trial								-	-	-	-	-

Conduit Pharmaceuticals Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Conduit Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK7) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

CDT:USA

Address

4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103

Website

https://www.conduitpharma.com

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Headlines

No Headlines